ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
5.69
+0.06 (1.07%)
Aug 7, 2026, 4:00 PM EDT - Market closed
ImageneBio Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 94.68 | 94.53 | 12.12 | 119.89 | 59.92 | 232.22 |
Short-Term Investments | 41.48 | 40.82 | - | 55.57 | 97.03 | - |
Cash & Short-Term Investments | 136.15 | 135.35 | 12.12 | 175.47 | 156.95 | 232.22 |
Cash Growth | 42.36% | 1016.92% | -93.09% | 11.80% | -32.41% | 42.91% |
Other Current Assets | 4.96 | 4.94 | 0.35 | 3.2 | 3.06 | 4.3 |
Total Current Assets | 141.11 | 140.29 | 12.47 | 178.66 | 160.01 | 236.52 |
Net Property, Plant & Equipment | 0.52 | 0.79 | 0.55 | 8.02 | 8.46 | 8.98 |
Other Long-Term Assets | 10.41 | 11.9 | 2.91 | 5.41 | 3.79 | 2.39 |
Total Assets | 152.05 | 152.98 | 15.92 | 192.09 | 172.26 | 247.88 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.98 | 1.44 | 5.29 | 2.07 | 2.09 | 2.38 |
Accrued Expenses | 3.68 | 7.53 | 3.46 | 8.58 | 8.34 | 5.85 |
Current Portion of Long-Term Debt | - | - | 7.5 | - | - | - |
Current Portion of Leases | 1.91 | 2.26 | 0.31 | 3.56 | 1.91 | 1.85 |
Unearned Revenue | - | - | 0.65 | - | 9.16 | 17.1 |
Total Current Liabilities | 6.57 | 11.23 | 17.21 | 14.21 | 21.5 | 27.19 |
Long-Term Leases | - | 0.71 | 0.24 | 7.18 | 3.79 | 5.14 |
Other Long-Term Liabilities | 3.4 | 7.89 | - | 0.95 | - | 7.68 |
Total Long-Term Liabilities | 3.4 | 8.6 | 0.24 | 8.13 | 3.79 | 12.81 |
Total Liabilities | 9.97 | 19.84 | 17.45 | 22.34 | 25.29 | 40 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Preferred Stock | - | - | 18.97 | - | - | - |
Common Stock | 0.01 | 0.01 | 0 | 0.05 | 0.04 | 0.04 |
Additional Paid-in Capital | 392.96 | 363.09 | 2.16 | 452.14 | 361.92 | 353.3 |
Accumulated Other Comprehensive Income | -0.05 | 0.09 | -1.79 | -0.05 | -0.76 | - |
Retained Earnings | -250.85 | -230.05 | -179.9 | -282.39 | -214.22 | -145.45 |
Total Common Shareholders' Equity | 142.07 | 133.14 | -160.57 | 169.76 | 146.97 | 207.88 |
Minority Interest | - | - | 159.04 | - | - | - |
Shareholders' Equity | 142.07 | 133.14 | -1.53 | 169.76 | 146.97 | 207.88 |
Total Liabilities & Equity | 152.05 | 152.98 | 15.92 | 192.09 | 172.26 | 247.88 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.91 | 2.98 | 8.05 | 10.74 | 5.69 | 6.99 |
Net Cash (Debt) | 134.24 | 132.37 | 4.07 | 164.73 | 151.25 | 225.23 |
Net Cash Growth | 49.21% | 3152.43% | -97.53% | 8.91% | -32.84% | 38.77% |
Net Cash Per Share | 12.22 | 27.18 | 0.84 | 47.36 | 50.16 | 96.58 |
Book Value | 142.07 | 133.14 | -160.57 | 169.76 | 146.97 | 207.88 |
Book Value Per Share | 12.93 | 27.33 | -32.96 | 48.81 | 48.73 | 89.14 |
Tangible Book Value | 142.07 | 133.14 | -160.57 | 169.76 | 146.97 | 207.88 |
Tangible Book Value Per Share | 12.93 | 27.33 | -32.96 | 48.81 | 48.73 | 89.14 |